inSeption Group

inSeption Group is a specialized clinical research organization (CRO) founded in 2019, headquartered in San Francisco, CA. It positions itself as a premium, client-centric alternative to large, commoditized CROs by offering deep therapeutic expertise in oncology, rare disease, and gene therapy, and a service model designed to integrate seamlessly with emerging and midsized biotech clients. The company's value proposition is built on high employee retention, a 94% repeat/referral business rate, and a focus on transparency and strategic partnership to improve clinical trial execution.

A human-capital-intensive clinical service delivery model featuring integrated Project Management, dedicated Regional Site Managers (RSMs) for consistent site contact, and embedded Clinical Science support, all built on a culture of low employee turnover and deep therapeutic expertise.

inSeption competes against large, global CROs (e.g., IQVIA, ICON, PPD) and mid-sized CROs. Its differentiation is not scale but a specialized, high-touch service model focused on complex therapies and deep client integration, targeting biotechs dissatisfied with the impersonal, high-volume approach of larger players.